India's Glenmark to study potential COVID-19 drug combination


Reuters | Bengaluru | Updated: 26-05-2020 11:10 IST | Created: 26-05-2020 10:55 IST
India's Glenmark to study potential COVID-19 drug combination
Representative Image Image Credit: ANI
  • Country:
  • India

Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir as a potential COVID-19 treatment.

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback